- Home
- CUE vs CODA Comparison
CUE vs CODA Comparison
Compare CUE & CODA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- CODA
- Stock Information
- Founded
- CUE 2014
- CODA 1994
- Country
- CUE United States
- CODA United States
- Employees
- CUE N/A
- CODA N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- CODA Industrial Machinery/Components
- Sector
- CUE Health Care
- CODA Industrials
- Exchange
- CUE Nasdaq
- CODA Nasdaq
- Market Cap
- CUE 91.9M
- CODA 92.5M
- IPO Year
- CUE 2018
- CODA N/A
- Fundamental
- Price
- CUE $1.42
- CODA $7.96
- Analyst Decision
- CUE Strong Buy
- CODA Strong Buy
- Analyst Count
- CUE 5
- CODA 1
- Target Price
- CUE $5.00
- CODA $11.00
- AVG Volume (30 Days)
- CUE 270.9K
- CODA 37.2K
- Earning Date
- CUE 03-10-2025
- CODA 03-17-2025
- Dividend Yield
- CUE N/A
- CODA N/A
- EPS Growth
- CUE N/A
- CODA 14.29
- EPS
- CUE N/A
- CODA 0.32
- Revenue
- CUE $9,532,000.00
- CODA $20,316,161.00
- Revenue This Year
- CUE $73.11
- CODA $22.31
- Revenue Next Year
- CUE $11.02
- CODA $12.02
- P/E Ratio
- CUE N/A
- CODA $24.41
- Revenue Growth
- CUE 149.53
- CODA 4.98
- 52 Week Low
- CUE $0.45
- CODA $5.41
- 52 Week High
- CUE $2.58
- CODA $9.89
- Technical
- Relative Strength Index (RSI)
- CUE 54.92
- CODA 44.55
- Support Level
- CUE $1.27
- CODA $7.75
- Resistance Level
- CUE $1.45
- CODA $8.13
- Average True Range (ATR)
- CUE 0.13
- CODA 0.36
- MACD
- CUE 0.00
- CODA -0.04
- Stochastic Oscillator
- CUE 77.86
- CODA 21.65
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.
About CODA Coda Octopus Group Inc. Common stock
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. It operates in two segments: Marine Technology Business and Marine Engineering Business. The Technology Business develops proprietary solutions for both the commercial and defense subsea market. Its solutions include hardware and software for Geophysical Systems, Motion & Positioning Systems, and Real-Time Volumetric Imaging Sonar. The Engineering Business segment provides engineering services to a range of clients in the defense markets. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Marine Technology Business segment.